451 related articles for article (PubMed ID: 26979921)
1. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.
Gribkoff VK; Kaczmarek LK
Neuropharmacology; 2017 Jul; 120():11-19. PubMed ID: 26979921
[TBL] [Abstract][Full Text] [Related]
2. Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases.
Bishop KM
Neuropharmacology; 2017 Jul; 120():56-62. PubMed ID: 27998711
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.
Geerts H; Wikswo J; van der Graaf PH; Bai JPF; Gaiteri C; Bennett D; Swalley SE; Schuck E; Kaddurah-Daouk R; Tsaioun K; Pelleymounter M
CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):5-20. PubMed ID: 31674729
[TBL] [Abstract][Full Text] [Related]
4. Targeting neuronal function for CNS drug discovery.
Hempel CM; Werley CA; Dempsey GT; Gerber DJ
Drug Discov Today Technol; 2017 Mar; 23():17-25. PubMed ID: 28647082
[TBL] [Abstract][Full Text] [Related]
5. Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.
Yokley BH; Hartman M; Slusher BS
ACS Chem Neurosci; 2017 Mar; 8(3):429-431. PubMed ID: 28195461
[TBL] [Abstract][Full Text] [Related]
6. Translational CNS medicines research.
Palmer AM; Alavijeh MS
Drug Discov Today; 2012 Oct; 17(19-20):1068-78. PubMed ID: 22580061
[TBL] [Abstract][Full Text] [Related]
7. Proceedings of the 2013 CINP summit: innovative partnerships to accelerate CNS drug discovery for improved patient care.
Phillips AG; Hongaard-Andersen P; Moscicki RA; Sahakian B; Quirion R; Krishnan KR; Race T
Int J Neuropsychopharmacol; 2014 Dec; 18(3):. PubMed ID: 25542690
[TBL] [Abstract][Full Text] [Related]
8. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
Brunner D; Balcı F; Ludvig EA
Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
[TBL] [Abstract][Full Text] [Related]
9. CNS drug development - lost in translation?
Talevi A; Bellera CL; Di Ianni M; Gantner M; Bruno-Blanch LE; Castro EA
Mini Rev Med Chem; 2012 Sep; 12(10):959-70. PubMed ID: 22420574
[TBL] [Abstract][Full Text] [Related]
10. Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.
Amigoni F; Legnaghi E; Pevarello P
Pharm Pat Anal; 2012 May; 1(2):177-92. PubMed ID: 24236782
[TBL] [Abstract][Full Text] [Related]
11. Potential medicinal value of celastrol and its synthesized analogues for central nervous system diseases.
Bai X; Fu RJ; Zhang S; Yue SJ; Chen YY; Xu DQ; Tang YP
Biomed Pharmacother; 2021 Jul; 139():111551. PubMed ID: 33865016
[TBL] [Abstract][Full Text] [Related]
12. Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning.
Morofuji Y; Nakagawa S
Curr Pharm Des; 2020; 26(13):1466-1485. PubMed ID: 32091330
[TBL] [Abstract][Full Text] [Related]
13. Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward.
Geerts H; Kennis L
Future Med Chem; 2014; 6(16):1757-69. PubMed ID: 25574530
[TBL] [Abstract][Full Text] [Related]
14. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
Sahu JK; Mishra AK
Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
[TBL] [Abstract][Full Text] [Related]
15. Challenges in the search for drugs to treat central nervous system disorders.
Enna SJ; Williams M
J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
[TBL] [Abstract][Full Text] [Related]
16. CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
Hutson PH; Clark JA; Cross AJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():171-187. PubMed ID: 27575715
[TBL] [Abstract][Full Text] [Related]
17. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
Cole PE; Schwarz AJ; Schmidt ME
Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
[TBL] [Abstract][Full Text] [Related]
18. Zebrafish models in neuropsychopharmacology and CNS drug discovery.
Khan KM; Collier AD; Meshalkina DA; Kysil EV; Khatsko SL; Kolesnikova T; Morzherin YY; Warnick JE; Kalueff AV; Echevarria DJ
Br J Pharmacol; 2017 Jul; 174(13):1925-1944. PubMed ID: 28217866
[TBL] [Abstract][Full Text] [Related]
19. Start small and stay small. Minimizing attrition in the clinic with a focus on CNS therapeutics.
Nienaber V
Curr Top Med Chem; 2009; 9(18):1688-704. PubMed ID: 19929834
[TBL] [Abstract][Full Text] [Related]
20. Overview of the use of transgenic animals in CNS drug discovery.
Nestler EJ; Olivier B
Curr Protoc Pharmacol; 2001 May; Chapter 5():Unit5.20. PubMed ID: 21965073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
